Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer - Petrylak, Daniel P.; Kantoff, Philip; Vogelzang, Nicholas J.; Mega, Anthony; Fleming, Mark T.; Stephenson, Joe J.; Frank, Richard; Shore, Neal D.; Dreicer, Robert; McClay, Edward F.; Berry, William R.; Agarwal, Manish; et al. (The Prostate, 2019)
Keywords: Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal, Humanized; antibody‐drug conjugate; Antigens; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Antitumor activity; Castration; Chemotherapy; Cytotoxicity; Dose-Response Relationship, Drug; Drug dosages; Drug Monitoring - methods; Drug Resistance, Neoplasm; Humans; Immunoglobulin G; Immunoglobulins, Intravenous - administration & dosage; Immunoglobulins, Intravenous - pharmacokinetics; Intravenous administration; Male; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasm Staging; Neoplastic Cells, Circulating - pathology; Neutropenia; Oligopeptides - metabolism; Peripheral neuropathy; Pharmacokinetics; Prostate cancer; Prostate-Specific Antigen - blood; prostate‐specific membrane antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - immunology; Prostatic Neoplasms - pathology; Treatment Outcome; Tumor cells; Xenograft Model Antitumor Assays; Prostate cancer; antibody-drug conjugate; prostate-specific membrane antigen